Pharmacologic class: Mu-opioid receptor antagonist (peripherally acting)
Therapeutic class: Opioid
Pregnancy risk category B
Selectively antagonizes opioid binding at mu-opioid receptors (such as those in GI tract) while having restricted ability to cross blood-brain barrier, thereby decreasing constipating effects of opioids without altering analgesic effects on CNS
Solution for injection: 12 mg/0.6 ml in single-use vials
⊘Indications and dosages
➣ Opioid-induced constipation in patients with advanced illness who are receiving palliative care and haven't responded adequately to laxatives
Adults weighing 62 to less than 114 kg (136 to less than 251 lb): 12 mg subcutaneously every other day as needed, but no more frequently than one dose in 24 hours
Adults weighing 38 to less than 62 kg (84 to less than 136 lb): 8 mg subcutaneously every other day as needed, but no more frequently than one dose in 24 hours
Adults weighing outside above ranges: 0.15 mg/kg subcutaneously every other day as needed, but no more frequently than one dose in 24 hours
• Severe renal impairment (creatinine clearance less than 30 ml/minute)
• Known or suspected mechanical GI obstruction
Use cautiously in:
• renal impairment
• severe or persistent diarrhea, known or suspected GI tract lesions
• pregnant or breastfeeding patients
• children (safety and efficacy not established).
• Once drawn into syringe, if drug won't be given immediately, store at ambient room temperature and administer within 24 hours.
CNS: dizziness, malaise
GI: nausea, abdominal pain, diarrhea, flatulence abdominal cramping, GI perforation
Other: flushing, pain, diaphoresis
☞ Monitor patient for severe or persistent diarrhea and signs and symptoms of GI perforation. Discontinue drug if either occurs.
• Teach patient who will take drug at home how to prepare and administer it and discard supplies properly.